Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer — Stella

Home/Colorectal Cancer/FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

View on ClinicalTrials.gov

Recruiting

Back to Colorectal Cancer trials

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Germany

University Hospital Tuebingen, Tübingen, Baden-Wurttemberg

Key details

Phase

Early testing

Sponsor

German Cancer Research Center

Enrollment target

~89 participants

Started

January 2024

Primary completion

October 2026

Age range

18 Years and older

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.